Covaxin junior for the 2-18 age group in India
By MYBRANDBOOK
Following the news that the Subject Expert Committee (SEC) provided a positive recommendation to the Drug Controller General of India (DCGI) for the use of Bharat Biotech’s Covaxin in 2-18 years age group for COVID-19;
“Covaxin may become the second indigenous vaccine to get approval below 18 years for COVID-19; however, it will be the only vaccine to cover the 2-18 years age group in India. Zydus Cadila’s ZyCov-D is the first vaccine in India to get approval for the 12-18 years age group and was approved in India on 20 August 2021. However, it is not yet part of the COVID-19 vaccination drive as price negotiations with the Indian government are still ongoing.
“Covaxin’s PII/PIII trial was conducted in India by segregating children into age groups ≤18 - >12, ≤12 ->6, ≤ 6 - >2 years and 28 days between the first and second doses. Unfortunately, Covaxin’s PII/PIII trial results are not yet available publicly available.
“Following approval, Covaxin will compete with ZyCov-D for; however, compared to ZyCov-D – Covaxin already has a well-established supply chain and requires one fewer dose than ZyCov-D. Moreover, the pricing of Covaxin would be less compared to ZyCov-D, especially for private hospitals. In addition, the majority of the vaccination drive in India is dominated by government hospitals.
“Bharat Biotech expects to supply 55 million doses of Covaxin per month from October from the existing 35 million doses. In contrast, Zydus Cadila is expected to produce 10 million doses of ZyCov-D per month.
India is ranked second globally after China in terms of the total number of COVID-19 vaccine doses administered at over 954 million doses as of 11 October 2021. Covaxin is the second-most popular vaccine after Covishield as part of the COVID-19 vaccination drive in India. The country has administered over 110 million doses of Covaxin.
“In the near future, the overall competition in the below 18 years age group will intensify with potential approvals. However, the success of the new vaccines will be dependent on meeting the demand in a swift manner.”
Legal Battle Over IT Act Intensifies Amid Musk’s India Plans
The outcome of the legal dispute between X Corp and the Indian government c...
Wipro inks 10-year deal with Phoenix Group's ReAssure UK worth
The agreement, executed through Wipro and its 100% subsidiary,...
Centre announces that DPDP Rules nearing Finalisation by April
The government seeks to refine the rules for robust data protection, ensuri...
Home Ministry cracks down on PoS agents in digital arrest scam
Digital arrest scams are a growing cybercrime where victims are coerced or ...
Icons Of India : Dr. Arvind Gupta
Arvind Gupta is the Head and Co-Founder of the Digital India Foundatio...
ICONS OF INDIA : RAJESH NAMBIAR
Rajesh leads the company’s India associates and enhances relationshi...
Icons Of India : Harsh Jain
Harsh Jain, the co-founder of Dream 11, the largest fantasy sports web...
DRDO - Defence Research and Development Organisation
DRDO responsible for the development of technology for use by the mili...
STPI - Software Technology Parks of India
STPI promotes and facilitates the growth of the IT and ITES industry i...
CERT-IN - Indian Computer Emergency Response Team
CERT-In is a national nodal agency for responding to computer security...
Indian Tech Talent Excelling The Tech World - NEAL MOHAN, CEO - Youtube
Neal Mohan, the CEO of YouTube, has a bold vision for the platform’s...
Indian Tech Talent Excelling The Tech World - JAY CHAUDHRY, CEO – Zscaler
Jay Chaudhry, an Indian-American technology entrepreneur, is the CEO a...
Indian Tech Talent Excelling The Tech World - Vinod Dham, Founder & Executive Managing Partner, IndoUS Venture Partners
Vinod Dham, known as the “Father of the Pentium Chip,” has left an...